Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17689282 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Shenberger JS, et al. (2007) Roles of mitogen-activated protein kinase signal-integrating kinases 1 and 2 in oxidant-mediated eIF4E phosphorylation. Int J Biochem Cell Biol 39, 1828-42 17689282
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S209-p - eIF4E (human)
Orthologous residues
eIF4E (human): S209‑p, eIF4E iso4 (human): S237‑p, eIF4E (mouse): S209‑p, eIF4E (rat): S209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Mnk1 (mouse) genetic knockout/knockin of upstream enzyme, co-immunoprecipitation, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
CGP57380 H2O2 inhibit treatment-induced increase

T250-p - Mnk1 (human)
Orthologous residues
Mnk1 (human): T250‑p, Mnk1 iso2 (human): T209‑p, Mnk1 (mouse): T209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
CGP57380 increase
H2O2 CGP57380 augment treatment-induced increase

T255-p - Mnk1 (human)
Orthologous residues
Mnk1 (human): T255‑p, Mnk1 iso2 (human): T214‑p, Mnk1 (mouse): T214‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
CGP57380 increase
H2O2 CGP57380 augment treatment-induced increase

S209-p - eIF4E (mouse)
Orthologous residues
eIF4E (human): S209‑p, eIF4E iso4 (human): S237‑p, eIF4E (mouse): S209‑p, eIF4E (rat): S209‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Mnk1 (mouse) genetic knockout/knockin of upstream enzyme, co-immunoprecipitation, phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
H2O2 Mnk1 (mouse) inhibit treatment-induced increase knockout
H2O2 Mnk2 (mouse) inhibit treatment-induced increase knockout (slight effect)
Mnk1 (mouse) Mnk2 (mouse) augment treatment-induced decrease knockout

T180-p - P38A (mouse)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
H2O2 Mnk1 (mouse) no effect upon treatment-induced increase knockout
H2O2 Mnk2 (mouse) inhibit treatment-induced increase knockout

Y182-p - P38A (mouse)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
H2O2 increase
H2O2 Mnk1 (mouse) no effect upon treatment-induced increase knockout
H2O2 Mnk2 (mouse) inhibit treatment-induced increase knockout


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.